New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations.
Sign Up to like & getrecommendations! Published in 2019 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.9b00273
Abstract: We report a novel negamycin derivative TCP-1109 (13x) which serves as a potent readthrough drug candidate against nonsense-associated diseases. We previously demonstrated that TCP-112 (7), a nor-compound of native 3-epi-deoxynegmaycin, showed a higher readthrough activity… read more here.
Keywords: tga; compound; potent readthrough; nonsense mutations ... See more keywords